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Abstract: The insulin resistance syndrome (INSR) is associated with increased cardiovascular 
risk, and affects up to 25% of the Australian population aged 20 years. Increased arterial stiff-
ness has been proposed as a common pathway by which INSR leads to increased cardiovascular 
risk. We have reviewed the role of nitric oxide (NO) and angiotensin II receptors in the modu-
lation of arterial stiffness in the setting of insulin resistance. There is emerging evidence that 
early stages of INSR may be characterized by increased basal nitric oxide activity and increased 
activity of non-NO vasodilators such as endothelial derived hyperpolarization factor (EDHF) 
which is manifest by reduced arterial stiffness. Depletion of NO or ineffectiveness of NO medi-
ated vasodilator mechanisms associated with the progression of INSR to type 2 diabetes may 
result in increased arterial stiffness, which predicts the development of cardiovascular disease. 
Thus in the early stages of INSR, increased NO and EDHF activity may represent compensatory 
mechanisms to early vascular damage. The renin-angiotensin system is activated in diseased 
vascular beds, with up regulation of the two known angiotensin II receptors: the angiotensin II 
type 1 receptor (AT1R) and the angiotensin II type 2 receptor (AT2R). Increased AT1R medi-
ated activity in the vasculature is central to the development of increased arterial stiffness and 
is enhanced in INSR states. AT2R activity is increased in early in INSR and may contribute to 
the apparent increase in basal NO activity. AT1R blockade may therefore be valuable treatment 
for early INSR as antagonism of AT1 receptors would allow angiotensin II to act unopposed 
at AT2 receptors.
Keywords: arterial stiffness, insulin resistance, nitric oxide, AT1 receptor, AT2 receptor, 
diabetes, insulin resistance, obesity
Introduction
Insulin resistance (INSR) is a metabolic abnormality resulting from an impaired 
physiological response to insulin, and is present in disease states such as type II 
diabetes mellitus (DM), hypertension, chronic kidney disease and obesity. Of itself, 
or as part of the “deadly quartet” of cardiometabolic abnormalities making up the 
INSR syndrome (including hypertension, atherogenic dyslipidemia, and central 
obesity), INSR is associated with increased cardiovascular risk. Precise ﬁ  gures for 
the prevalence of INSR is not available, but the INSR syndrome affects up to 25% of 
the Australian population aged 20 years.1 With the median age and weight of the 
Australian population rising, INSR and its complications are emerging to be a major 
public health problem.
Increased arterial stiffness has been proposed as a common pathway by which INSR 
leads to increased cardiovascular risk.2–4 It is an established predictor of cardiovascular 
disease,2–4 and is implicated in the development of isolated systolic hypertension: a 
major cause of cardiovascular morbidity especially in the elderly. Prospective studies 
have shown that patients with the INSR syndrome have a greater increase in arterial 
stiffness with age compared with those without.5,6 Arterial stiffness is a complex 
phenomenon, involving structural (extracellular matrix and luminal pressure), cellular Vascular Health and Risk Management 2009:5 74
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(endothelial cells and vascular smooth muscle cells) and 
functional elements of the vessel wall. Structural changes 
occur in normal individuals from age twenty,7,8 with a reduc-
tion in elastic tissue, accompanied by its fragmentation and 
degeneration.
The cellular and functional elements contributing to arte-
rial stiffness is less well established. The endothelium and 
vascular smooth muscle cells (VSMCs) interact in a complex 
manner to modulate arterial tone, and the pathways mediating 
these interactions are still controversial. This review focuses 
on new concepts involving the role of nitric oxide (NO) and 
the angiotensin II receptors in the modulation of arterial 
stiffness, in the early stages of INSR.
NO is synthesized by three isozymes of the enzyme 
NO synthase (NOS) iNOS, nNOS and eNOS. iNOS is an 
inducible form of the enzyme that is activated in inﬂ  ammatory 
response. nNOS is a constitutive enzyme located in neuronal 
tissue where NO acts as a modulating neurotransmitter. NO is 
synthesized in the endothelium by a constitutive NO synthase 
(e-NOS).9 Endothelial production of NO has a vasodilatory 
effect and anti-atherogenic properties, including inhibition 
of VSMC proliferation and migration, platelet activation and 
adhesion and leukocyte adhesion and migration.10
Endothelial function can be assessed with a variety of 
techniques, with forearm blood ﬂ  ow studies after intra-
brachial arterial infusion of vasoactive substances being 
widely accepted as the gold standard. Endothelial dysfunc-
tion, demonstrated by reduced vasodilatory response to 
acetylcholine, have been observed in patients with impaired 
fasting glycemia11 and patients with established type 2 
diabetes.12,13 In recent years, studies of arterial stiffness 
changes following systemic administration of vasoactive 
medications known to affect endothelial function, such as 
beta-2 adrenoceptor agonists and the NO synthase inhibitor 
L-nitro monomethyl arginine (L-NMMA) have been 
proposed to be acceptable non-invasive techniques for the 
measurement of endothelial function.14,15 Chowienczyk and 
colleagues demonstrated signiﬁ  cant reductions in reﬂ  ection 
index (RI), a measure of small to medium sized arterial 
stiffness using digital photoplethysmography, after systemic 
administration of albuterol (which causes vasodilation via 
beta-2 receptor activation of endothelial NO formation) 
and glyceryl trinitrate (GTN) a direct dilator of VSMCs. 
Concurrent intravenous administration of the NO-synthase 
inhibitor, L-NMMA, blunted the RI response to albuterol but 
not to GTN,14 illustrating that small to medium-sized arterial 
stiffness is at least in part, dependent on the integrity of the 
endothelial L-arginine-NO pathway (Figure 1).16,17
There are several reports of arterial stiffness changes in 
INSR states18–22 and it is generally accepted that increased 
arterial stiffness heralds the onset of cardiovascular disease In 
some individuals, this can occur as early as adolescence.23–25 
This is well documented and will not be explored here further. 
There is emerging evidence however, of a stage of vascular 
change in early INSR that is characterized by increased basal 
NO levels and low to normal arterial stiffness. Mangoni and 
colleagues observed that young, obese, normotensive, and 
insulin-resistant subjects had signiﬁ  cantly increased radial 
artery diameter at baseline compared with lean controls26 
and induction of forearm ischemia by suprasystolic cuff 
Figure 1 Changes in responsiveness in small to medium sized artery compliance in patients with early insulin resistance syndrome. There is increased responsiveness to 
angiotensin II (AT2) mediated by both AT1 and AT2 receptors producing decreased and increased compliance respectively.   There is also increased basal nitric oxide activity 
producing an increase in compliance when measured as the reduction in compliance to nitric oxide synthase inhibition.
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compression of the brachial artery produced signiﬁ  cantly 
increased radial artery compliance in these subjects. 
A similar phenomenon has been described in subjects with 
mild essential hypertension.27 Recently, we observed that 
normotensive patients with the early INSR syndrome (using 
the International Diabetes Federation criteria) had signiﬁ  -
cantly reduced baseline arterial stiffness indices (large arte-
rial stiffness index: SI, and reﬂ  ection index: RI, a measure 
of small to medium-sized arterial stiffness) using digital 
photo plethysmography compared with age and sex-matched 
normal controls (NCs).28 Intravenous infusion of L-NMMA 
(3 mg/kg) in both groups produced a signiﬁ  cantly greater 
increase in small to medium artery stiffness (signiﬁ  cantly 
increased % change in RI) in INSR subjects compared with 
the NCs. We concluded that increased basal NO production 
may contribute to the reduced baseline arterial stiffness 
indices observed in INSR subjects, and may be a compensa-
tory mechanism to early vascular change in these individuals. 
To our knowledge, no other studies using other methods 
of measuring arterial compliance have been performed in 
patients with INSR.
Similarly, increased basal NO levels have been observed 
in subjects with early type I and II diabetes mellitus,29–31 and 
may be accompanied by an increase in the activity non-NO 
vasodilator agents such as endothelial hyperpolarizing factor 
(EDHF).30 Furthermore, increased EDHF activity may play 
a relatively greater role when NO mechanisms fail32 during 
the progression of early INSR to type 2 diabetes. There is 
evidence to suggest that the development of microvascular 
disease in diabetes is accompanied by depletion of basal NO 
levels and impairment of non-NO vasodilator mechanisms. 
This is important, as the onset of microvascular disease in 
diabetics is associated with a marked increase in mortality, 
to as much as 40-fold in those with clinical nephropathy 
(urinary albumin excretion 300 mg/day), compared to 
those without.33
In type I diabetes, no difference in endothelial function 
and basal NO levels were demonstrated in patients without 
microvascular disease and non-diabetic controls.33,34 Impair-
ment in endothelial function and reduction in basal NO 
levels, however, were demonstrated in diabetic subjects 
with microvascular disease (and increased with severity of 
microvascular disease) compared to diabetics without micro-
vascular disease. The progression of impaired NO associated 
endothelial dysfunction appears to be a feature of both 
type 1 and type 2 diabetics with microvascular disease,35 
but the early increase in arterial compliance and increased 
basal NO activity may be a speciﬁ  c feature of early INSR. 
These ﬁ  ndings are in contrast with studies of late type 2 
diabetics, women with polycystic ovary disease and obese 
children where reduced basal arterial compliance has been 
reported.35,36
In type II diabetic subjects, basal plasma NO3
− levels 
(as a marker of basal nitric oxide levels) were found to be 
increased compared with nondiabetic controls.29 In addition, 
however, basal plasma NO3
− levels appeared to increase with 
severity of microvascular disease. Caution must be taken 
in interpreting the latter ﬁ  ndings however, as metabolism 
and renal excretion of NO3
− is reduced in advanced micro-
vascular disease (particularly nephropathy), which may be 
misinterpreted as increased basal NO production. Indeed, no 
signiﬁ  cant difference in NO2
− levels (another NO metabolite 
measured by the group as a marker of basal nitric oxide 
levels) were demonstrated between nondiabetic controls, 
diabetics without microvascular disease, and diabetics with 
microvascular disease.
In summary, basal NO levels regulate, at least in part, 
arterial tone. A compensatory increase in basal nitric oxide 
levels and possibly of non-NO vasodilators such as EDHF32 
may result in reduced baseline arterial stiffness early in 
INSR. Eventual depletion of NO may result in increased 
arterial stiffness, perhaps due to oxidation, which predicts the 
development of cardiovascular disease during the progression 
of early INSR to type 2 diabetes.
Angiotensin receptor-mediated 
responses
Clinical trials have consistently demonstrated the cardiorenal 
protective beneﬁ  ts of angiotensin-converting enzyme inhbi-
tors (ACE-I) and AII receptor blockers (ARBs) in high risk 
cardiovascular patients which are independent of its blood 
pressure-lowering effect.37–41 The precise mechanism for 
these effects is not certain, although exciting new concepts 
are emerging. Angiotensin II is the main effector hormone of 
the renin-angiotensin system. It binds to two main receptor 
subtypes: the angiotensin II type 1 receptor (AT1R) and 
the angiotensin II type 2 receptor (AT2R). The AT1R is 
expressed in various adult tissues, and mediates most of the 
well-known physiological and pathophysiological effects 
of AII. AT1R activity in the vasculature is central to the 
development of increased arterial stiffness which is enhanced 
in INSR states.7,42 AT1R activation in VSMCs have vaso-
constrictive, proliferative and inﬂ  ammatory effects43 and is 
responsible for the accumulation of extracellular matrix pro-
teins such as collagen.44 In the endothelium, the AT1R binds 
and directly alters e-NOS to inhibit its activity. It has potent Vascular Health and Risk Management 2009:5 76
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atherogenic effects by up-regulating expression of lectin-like 
oxidized low-density lipoprotein (LDL) receptor-1 (LOX-1, 
which induces uptake of oxidized LDL in the endothelial 
cell), impairing NO production, inducing white blood cell 
adhesion molecules and stimulating reactive oxygen species 
(ROS) production, mitogen-activated protein kinase (MAPK) 
and nuclear factor kappa B (NF-κB).45 Recently, the AT1R 
has been implicated in the inhibition of insulin-signaling 
pathways in both nondiabetic and diabetic rats, and may thus, 
itself, facilitate development of insulin resistance.46
AT2R expression declines rapidly after birth in humans, 
but is present in the vascular endothelium and other organs 
such as the ovary and uterus in adult humans.47 Its role 
in healthy individuals is debated, but there is evidence of 
up-regulation of AT2R expression during cardiovascular 
damage, such as in common carotid balloon injury,48 
hypertension,49 myocardial infarction, and heart failure,50,51 
where it mediates essentially opposing effects to the AT1R. 
This hypothesis is supported by our studies. In a double-
blinded, placebo-controlled cross-over model, healthy 
human volunteers were given an intravenous infusion of the 
highly selective AT2 receptor blocker, PD123319 (10 micro-
grams/min for 3 minutes).52 No signiﬁ  cant hemodynamic or 
arterial stiffness changes were demonstrated after PD123319 
infusion, compared with placebo infusion.53 In contrast, our 
study on individuals with HOMA-IR  2 (a measure of 
insulin resistance) and age- and sex-matched NCs given the 
same dose of intravenous PD123319 (10 micrograms/min for 
3 minutes), produced a signiﬁ  cantly greater increase in RI, 
or small to medium sized arterial stiffness with a concurrent 
rise in systemic vascular resistance index in INSR subjects54 
while no change occurred in normal controls (NCs). Inter-
estingly, baseline RI levels were lower in the subjects with 
early INSR consistent with the hypothesis that increased 
activity of both AT2 and NO medicated mechanisms lead 
to a reduction in RI in early INSR. This suggests functional 
expression of AT2R in small to medium sized arteries in 
patients with early INSR, but not in normal volunteers. The 
AT2R activity in INSR subjects may be a response to early 
vascular damage. Evidence that vascular damage occurs 
in INSR, presumably at a later stage than the subjects that 
we studied, and causes arterial stiffening was provided by 
Kim and colleagues who demonstrated reductions in large 
arterial stiffness indices with improved insulin sensitivity in 
INSR subjects treated with peroxisome-proliferator-activated 
receptor γ (PPAR-γ) agonists.55
In diseased vascular beds both AT1R and AT2R expression 
is upregulated.46 Increased vascular sensitivity to AII-induced 
vasoconstriction has previously been reported in patients with 
type 2 diabetes mellitus,56 suggesting upregulation of AT1R 
activity in these individuals. In support of this, in a previously 
described comparative study of subjects with early INSR and 
age and sex-matched NCs,28 infusion of AII (8, 16 ng/min for 
3 minutes) produced a signiﬁ  cantly greater increase in RI in 
INSR subjects. The increase in RI could not be attributed to 
reduced basal NO levels because, as previously discussed, 
we have, in fact, demonstrated increased basal NO activity 
in these subjects. The increase in RI therefore, is most likely 
attributable to increased AT1R activity in small to medium-
sized arteries in subjects with early INSR. In addition, in the 
same study, we demonstrated evidence of increased AT2R 
activity in subjects with the INSR syndrome. Infusion of the 
highly selective AT2R blocker, PD123319 (10, 20 micro-
grams/min for 3 minutes) produced a signiﬁ  cantly greater 
increase in RI in subjects with early INSR than in NCs where 
no signiﬁ  cant change occurred. Together, these results dem-
onstrate an increased activity of both AT1- and AT2-mediated 
responses in INSR. An AT2R-mediated increase in basal 
NO43,57 may, in fact, contribute to the apparent increase in 
basal NO oxide levels demonstrated after NOS blockade with 
L-NMMA in these subjects. Further studies with acetylcholine 
to directly stimulate NO formation may help clarify if there is 
increased NO formation in the INSR syndrome, independent 
of the effects of AT2R activation.
In summary, the combined vasodilator effects of increased 
basal NO levels and increased AT2R expression in INSR sub-
jects are likely to be signiﬁ  cant contributors to the observed 
increased arterial compliance in the early stages of INSR 
states, and may represent an early response to vascular dam-
age,58 some of which is induced by increased AT1R expres-
sion. AT1R blockade may therefore be a useful treatment for 
INSR states, with its triple effect of blocking harmful AT1R-
mediated vascular effects, increased AT2R expression,59 and 
increased AII formation with unopposed AT2R activation.
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